| 2016-11-30 09:33:08|
ACOR 09:33 11/30 11/30/16
Acorda Therapeutics upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov upgraded Acorda Therapeutics to Overweight from Not rated and Neutral prior to the restriction. The analyst said upcoming Phase 3 data for CVT-301 and a decision in the pending Ampyra IP cases have the potential to act as catalysts.